Rupatadine in allergic rhinitis and chronic urticaria

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 63, Issue SUPPL. 87, 2008, Pages 5-28

  Mullol, J ^a   Bousquet, J ^b   Bachert, C ^c   Canonica, W G ^d   Gimenez Arnau, A ^e   Kowalski, M L ^f   Marti Guadano E ^g   Maurer, M ^h   Picado, C ⁱ   Scadding, G ^j   Van Cauwenberge, P ^c  

^a HOSPITAL CLÍNIC   (Spain)

^b INSERM   (France)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY OF GENOA   (Italy)

^e HOSPITAL DEL MAR   (Spain)

^f MEDICAL UNIVERSITY OF LODZ   (Poland)

^g Fundacio Hospital Sant Pere Claver   (Spain)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

^j ROYAL NATIONAL THROAT NOSE AND EAR HOSPITAL   (United Kingdom)

more..

Author keywords

Allergic rhinitis; Antiallergic antihistamines; Chronic urticaria; H 1 receptor antagonists; PAF receptor antagonists; Rupatadine

Indexed keywords

1 ACETYL 4 (8 CHLORO 5,6 DIHYDRO 11H BENZO[5,6]CYCLOHEPTA[1,2 B]PYRIDIN 11 YLIDENE)PIPERIDINE; APAFANT; CD11B ANTIGEN; CD18 ANTIGEN; CETIRIZINE; CHLORPHENIRAMINE; CLEMASTINE; DESLORATADINE; DIPHENHYDRAMINE; EBASTINE; FOROPAFANT; GINKGOLIDE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYZINE; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; KETOTIFEN; LEVOCABASTINE; LORATADINE; MEPYRAMINE; MIZOLASTINE; RUPATADINE; TERFENADINE; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; THROMBOCYTE ACTIVATING FACTOR RECEPTOR AFFECTING AGENT; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CHRONIC URTICARIA; CLINICAL TRIAL; COGNITIVE DEFECT; DRIVING ABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HAY FEVER; HUMAN; IDIOPATHIC DISEASE; INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; PERENNIAL RHINITIS; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; QUALITY OF LIFE; RATING SCALE; REVIEW; SYMPTOMATOLOGY; WELLBEING;

ADOLESCENT; ANIMALS; ANTI-ALLERGIC AGENTS; CHILD; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; CYPROHEPTADINE; DOGS; HUMANS; PLATELET ACTIVATING FACTOR; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME; URTICARIA;

EID: 40749156700     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2008.01640.x     Document Type: Review

References (94)

1. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001 108 (Suppl. 5 S147 S334.
2. Holgate ST, Canonica GW, Simons FER, Taglialatela M, Tharp M, Timmerman H et al. Consensus group on new-generation antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003 33 : 1305 1324.
3. Howarth PH, Holmberg K. Allergic rhinitis an increasing clinical problem. Allergy 1995 50 : 4 5.
4. Weiss ST. Eat dirt - the hygiene hypothesis and allergic diseases. New Engl J Med 2002 347 : 930 931.
5. AAAAI, The Allergy Report. Available at: http://www.theallergyreport.com (accessed January 2008).
6. Meltzer EO. Does rhinitis compromise night-time sleep and daytime productivity? Clin Exp All Rev 2002 2 : 67 72.
7. Potter PC. Effectiveness and safety of new-generation antihistamines in allergenic rhinitis and urticaria. SA Fam Pract 2005 47 : 24 28.
8. Bousquet J, Van Cauwenberge P, Bachert C, Canonica GW, Demoly P, Durham R et al. Requirements for medications commonly used in the treatment of allergic rhinitis. Allergy 2003 58 : 192 197.
9. 2LEN). Allergy 2006 61 : 1086 1096.
10. Van Cauwenberge P, Bachert C, Passalacqua G et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000 55 : 116 134.
11. 2LEN/EDF guideline: management of urticaria. Allergy 2006 61 : 321 331.
12. i antihistamines in the treatment of chronic idiopathic urticaria. Cutis 2005 76 : 118 126.
13. Gregory C, Cifaldi M, Tanner LA. Targeted intervention programs: creating a customized practice model to improve the treatment of allergic rhinitis in a managed care population. Am J Manag Care 1999 5 : 485 496.
14. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic asthma in Europe. Eur Respir J 2004 24 : 758 764.
15. Nathan RA, Meltzer EO, Selner JC, Storms W. Prevalence of allergic rhinitis in the United States. J Allergy Clin Immunol 1997 99 (6 Suppl. 2 S808 S814.
16. Foley S, Hamid Q. Inflammatory patterns in allergic rhinitis. Clin Exp Allergy Rev 2006 6 : 91 95.
17. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001 108 (Suppl. B S2 S8.
18. Spector SL. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 1997 99 (Suppl. S773 S780.
19. Grossmann J. One airway, one disease. Chest 1997 111 (Suppl. 2 11S 16S.
20. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997 136 : 197 201.
21. Greaves MW. Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol 2003 3 : 363 368.
22. Grattan CEH. Towards rationalizing the nomenclature and classification of urticaria: some guidance on guidelines. Clin Exp Allergy 2007 37 : 625 626.
23. 2LEN guideline definition, classification and diagnosis of urticaria. Allergy 2006 61 : 316 320.
24. Negro-Alvarez JM, Miraller-López JC. Chronic idiopathic urticaria treatment. Allergol Immunopathol 2001 29 : 129 132.
25. Kozel MM, Sabroe RA. Chronic urticaria: aetiology, management and current and future treatment options. Drugs 2004 64 : 2515 2536.
26. Garcia-Rafanell J. Rupatadine fumarate: antiallergic, histamine and PAF antagonist. Drugs Fut 1996 21 : 1033 1036.
27. Van Den Anker-Rakhmanina NY. Rupatadine. Curr Opin Anti-inflamm Immumomodul Invest Drugs 2000 2 : 127 132.
28. I receptor and platelet-activating factor (PAF) antagonist: a review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today (Barc) 2003 39 : 451 468.
29. Picado C. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin Pharmacother 2006 7 : 1989 2001.
30. Keam SJ, Plosker GL. Rupatadine: a review of its use in the management of allergic disorders. Drugs 2007 67 : 457 474.
31. Howarth PH, Salagean M, Dokic D. Allergic rhinitis: not purely a histamine-related disease. Allergy 2000 55 : 7 16.
32. Quraishi SA, Davies MJ, Craig TJ. Inflammatory responses in allergic rhinitis: traditional approaches and novel treatment strategies. J Am Osteopathol Assoc 2004 104 (Suppl. 5 S7 S15.
33. Pearlman DS. Pathophysiology of the inflammatory response. J Allergy Clin Immunol 1999 104 : S132 S137.
34. Bascom R, Pipkorn U, Proud D, Dunette S, Gleich GJ, Lichtenstein LM et al. Major basic protein and eosinophils-derived neurotoxin concentrations in nasal-lavage fluid after antigen challenge: effect of systemic corticosteroids and relationship to eosinophil influx. J Allergy Clin Immunol 1989 84 : 338 346.
35. Bascom R, Pipkorn U, Lichtenstein LM, Naclerio RM. The influx of inflammatory cells into nasal washings during the late-phase response to antigen challenge. Effect of systemic steroid pretreatment. Am Rev Respir Dis 1988 138 : 406 412.
36. Horak F. Clinical advantages of dual activity in allergic rhinitis. Allergy 2000 55 (Suppl. 64 34 39.
37. Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther 1997 280 : 114 121.
38. Barrón S, Ramis I, Garcia-Rafanell J, Merlos M. Inhibitory activity of rupatadine on pro-inflammatory cytokine production, relationship with binding affinity. Methods Find Exp Clin Pharmacol 2005 27 (Suppl. 2 161 162.
39. Giral M, Balsa D, Ferrando R, Merlos M, Garcia-Rafanell J, Forn J. CNS activity profile of rupatadine fumarate, a new dual receptor antagonist of platelet-activating factor (PAF) and histamine. Allergy 1998 53 (Suppl. 131.
40. Merlos M, Balsa D, Giral M, Ferrando R, Garcia-Rafanell J, Forn J. Inhibition of rat peritoneal mast cell exocytosis by rupatadine fumarate: a study with different secretagogues. Methods Find Exp Clín Pharmacol 1997 19 (Suppl. A 148.
41. Merlos M, Ferrando R, Giral M, Ramis I, Forn J. Effect of topical rupatadine in experimental conjunctivitis in guinea pigs: macroscopic evaluation of ocular lesions. J Allergy Clin lmmunol 2001 107 (Suppl. 2 S310.
42. Queralt M, Merlos M, Giral M, Puigdemont A. Dual effect of a new compound, rupatadine, on edema induced by platelet-activating factor and histamine in dogs: comparison with antihistamines and PAF antagonists. Drug Dev Res 1996 39 : 12 18.
43. Queralt M, Brazis P, Merlos M, Puigdemont A. lnhibitory effects of rupatadine on mast cell histamine release and skin wheal development induced by Ascaris suum in hypersensitive dogs. Drug Dev Res 1998 44 : 49 55.
44. Queralt M, Brazís P, Merlos M, de Mora F, Puigdemont A. In vitro inhibitory effect of rupatadine on histamine and TNF-α release from dispersed canine skin mast cells and the human mast cell line HMC-I. lnflamm Res 2000 49 : 355 360.
45. Ferrando R, Giral M, Balsa D, Merlos M, Garcia-Rafanell J, Forn J. Protective effect of rupatadine fumarate in experimental conjunctivitis in guinea pigs. Methods Find Exp Clin Pharmacol 1996 18 (Suppl. B 140.
46. Stuebner P, Horak F, Zieglmayer R, Arnáiz E, Leuratti C, Peréz I et al. Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber. Ann Allergy Asthma Immunol 2006 96 : 37 44.
47. Izquierdo I, Nieto C, Ramis J, Cooper M, Dewland P, Forn J. Pharmacokinetics and dose linearity of rupatadine fumarate in healthy volunteers. Methods Find Exp Clin Pharmacol 1997 19 (Suppl. A 189 203.
48. Barbanoj MJ, García-Gea C, Morte A, Izquierdo I, Pérez I, Jané F. Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers. Neuropsychobiology 2004 50 : 311 321.
49. Curtin ML. Current status of platelet-activating factor antagonists. Exp Opin Ther Patents 1998 8 : 703 711.
50. Marques SA, Dy LC, Southall MD, Yi Q, Smietana E, Kapur R et al. The platelet-activating factor receptor activates the extracellular signal-regulated kinase mitogen-activated protein kinase and induces proliferation of epidermal cells through an epidermal growth factor-receptor-dependent pathway. J Pharmacol Exp Ther 2002 300 : 1026 1035.
51. Merlos M, Ramis I, Balsa D, Queralt M, Brazis P, Pugidemont A. Inhibitory effect of rupatadine on TNF-α release from human monocytes and mast cell line HMC-1. J Allergy Clin lmmunol 2000 105 (Suppl. 1 S62.
52. Barrón S, Ramis I, Merlos M. Rupatadine inhibits the inflammatory component of allergic response: cytokine release, adhesion molecule expression and inflammatory cell recruitment. 23rd EAACI Congress, 12-16 June 2004, Amsterdam.
53. Merlos M, Giral M, Balsa D, Ferrando R, Garcia-Rafanell J, Forn J. Rupatadine inhibits the eosinophil recruitment in BAL fluid of ovalbumin-sensitized guinea pigs. J Allergy Clin lmmunol 1998 101 (Suppl. 1 S218.
54. Ramis I, Giral M, Ferrando R, Merlos M. Inhibition of PAF- and LTB4-induced human neutrophil chemotaxis by rupatadine using a new fluorescent chemotaxis assay. Allergy 2000 55 (Suppl. 63 94 95.
55. Barrón S, Roman J, Michelena P, Ramis I, Merlos M. Rupatadine inhibits cytokine production and NF-κB activity by histamine H1 receptor-dependent mechanism. Rev Rinol 2006 6 : 18.
56. Barrón S, Ramis I, Merlos M. Effect of rupatadine on lymphocyte cytokine production. Allergy Clin Immunol Int 2005 1 (Suppl. 1 427.
57. Scannell RT, Differding E, Talaga P. Dual acting antihistaminergic agents. Mini Rev Med Chem 2004 4 : 923 933.
58. Roumestan C, Henriquet C, Mathieu M, Bousquet J. Effects of rupatadine on inflammatory mediators and transcription factors: a comparison with desloratadine and levocetirizine Allergy Clin Immunol Int 2005 Suppl. 1 450.
59. Mion O, Mello Jr. J, Castro F, Cruz A, Mocelin M, Bogart P et al. Rupatadine fumarate is effective in the treatment of persistent allergic rhinitis: a multicentre study. Allergy 2007 62 (Suppl. 83 137.
60. Izquierdo I, Paredes I, Lurigados C, Sospedra E, Cooper M, Thomas H. A dose ranging study of rupatadine fumarate in patients with seasonal allergic rhinitis. Allergy 2000 55 (Suppl. 63 275.
61. Pérez I, De la Cruz G, Villa M, Izquierdo I. Rupatadine in allergic rhinitis: pooled analysis of efficacy data. Allergy 2002 57 (Suppl. 73 245.
62. I receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. J lnvestig Allergol Clin Immunol 2004 14 : 34 40.
63. Martinez-Cócera C, De Molina M, Marti-Guadaño E, Pola J, Conde J, Borja J et al. Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study. J lnvestig Allergol Clin Immunol 2005 15 : 22 29.
64. Guadaño EM, Serra-Batlles J, Meseguer J, Castillo JA, de Molina M, Valero A et al. Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study. Allergy 2004 59 : 766 771.
65. Valero A, Bartra J, Serrano C, Donado E, Garcia O, Izquierdo I et al. Rupatadine reduces nasal obstruction in allergen-induced rhinitis. Allergy 2007 62 (Suppl. 83 137 138.
66. Roger A, Arnáiz E, Valero A, De la Torre F, Castillo JA, Rivas P et al. Rupatadine 10 mg improves quality of life in long-term treatment of persistent allergic rhinitis [abstract no. 761 plus poster]. 25th EAACI Congress 10-14 June 2006, Vienna.
67. Fantin S, Maspero J, Bisbal C, Agache I, Donado E, Garcia O et al. A 12-week placebo-controlled study of rupatadine 10 mg once daily comparative with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis. In press, Allergy, 2008.
68. Gimenez-Arnau A, Pujol RM, Ianosi S, Kaszuba A, Malbran A, Poop G et al. Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicenter study. Allergy 2007 62 : 539 546.
69. Dubertret L, Zalupca L, Cristodoulo T, Benea V, Medina I, Fantin S et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Eur J Dermatol 2007 17 : 223 228.
70. Gimenez-Arnau A, Donado E, Arnaiz E, Perez I, Izquierdo I. Fast onset of action of rupatadine in the reduction of pruritus in patients suffering from chronic urticaria: pooled analysis. Allergy 2007 62 (Suppl. 83 306.
71. Gimenez-Arnau A, Perez I, Donado E, Pujol-Vallverdú RM, Arnaiz E, Izquierdo I. The use of a responder analysis to identify clinical meaningful differences in patients suffering from chronic urticaria following a 4-weeks treatment with rupatadine 10-and 20 mg. World Congress of Dermatology, 1-5 October 2007, Buenos Aries.
72. Juniper EF. Can quality of life be quantified? Clin Exp All Rev 2002 2 : 57 60.
73. Solans A, Merlos M, Antonijoan R, Barbanoj M, Donado E, Izquierdo I et al. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin: a randomized, crossover, multiple-dose open study. Allergy Clin Immunol Int 2005 Suppl. 1 159.
74. Solans A, Carbó M, Peña J, Nadal T, Izquierdo I, Merlos M. Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study. Clin Therap 2007 29 : 900 908.
75. Barbanoj MJ, García-Gea C, Antonijoan R et al. Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers. Hum Psychopharmacol Clin Exp 2006 21 : 13 26.
76. Efficacy Guideline. El: The extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions. ICH Harmonised Tripartate Guideline, 1995. Available at: http://www.ich.org (accessed January 2008).
77. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the clinical development of medicinal products for the treatment of allergic rhinoconjunctivitis. Available at: http://www.emea.europa. eu (accessed January 2008).
78. Valero A, Rivas P, Castillo JA, Borja J, Donado E, Arnaiz E et al. One year safety data of rupatadine 10 mg in patients with allergic rhinitis. 25th EAACI Congress 10-14 June, 2006, Vienna.
79. Gimenez-Arnau A, Pujol R, Donado E, Arnaiz E, Perez I, Izquierdo I. Safety profile of rupatadine in the treatment of chronic urticaria. Allergy 2007 62 (Suppl. 83 306.
80. Hove-Madsen L, Llach A, Molina CE, Prat-Vidal C, Farré J, Roura S et al. The proarrhythmic antihistaminic drug terfenadine increases spontaneous calcium release in human atrial myocytes. Eur J Pharmacol 2006 553 : 215 221.
81. 1 antihistamines upon the cardiovascular system. J Invest Allergol Clin Immunol 2006 16 (Suppl. 1 13 23.
82. Donado E, García O, Pérez I, Barbanoj M, Antonijoan R, Péna J et al. Cardiac safety of rupatadine according to the new ICH guideline: a "thorough QT/QTc study" [abstract no. 760 plus poster]. 25th EAACI Congress 10-14 June, 2006, Vienna.
83. Izquierdo I, Pérez I, Villa M, Giral M, Merlos M, Forn J. Lack of electrocardiographic effects of rupatadine, new nonsedating selective histamine H1-receptor and PAF antagonist. Allergy 2001 56 (Suppl. 68 212.
84. Giral M, Merlos M, Balsa D, Ferrando R, Garcia-Rafanell J, Forn J. Effects of rupatadine on cardiovascular profile in rats and guinea pigs: comparison with other nonsedating antihistamines. Allergy 1997 52 (Suppl. 37 44 45.
85. Ramis I, Giral M, Nieto C, Martel E, Merlos M. Lack of cardiotoxic effects of rupatadine in isolated Purkinje fibres and its relationship with rupatadine cardiac levels. Allergy 2000 55 (Suppl. 63 264.
86. Caballero R, Valenzuela C, Longobardo M, Tamargo J, Delpón E. Effects of rupatadine, a new dual antagonist of histamine and platelet-activating factor receptors, on human cardiac Kv1.5 channels. Br J Pharmacol 1999 128 : 1071 1081.
87. Antonijoan R, Garcia-Gea C, Ballester M, Donado E, Perez I, Blanch I et al. Rupatadine not potentiate the depressant CNS effects of benzodiazepines. Allergy 2007 62 (Suppl. 83 490.
88. Vuurman E, Theunissen E, van Oers A, van Leeuwen C, Jolles J. Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers. Human Psychopharmacol Clin Exp 2007 22 : 289 297.
89. Bousquet J. Is the impairment of quality of life acceptable for the patient? Clin Exp All Rev 2002 2 : 61 65.
90. Bachert C. Quality of life: improvement due to treatment. Clin Exp All Rev 2002 2 : 73 78.
91. Finlay AY, Khan GK. Dermatology Life Quality lndex (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 9 : 210 216.
92. Tillement J-P. Pharmacological profile of the new antihistamines. Clin Exp All Rev 2005 5 : 7 11.
93. Walsh GM. Anti-inflammatory properties of antihistamines: an update. Clin Exp All Rev 2005 5 : 21 25.
94. Devillier P. Comparing the new antihistamines: the role of pharmacological parameters. Clin Exp Allergy 2006 36 : 5 7.